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BEHAVIORAL AND PHARMACOLOGICAL CHARACTERIZATION OF A 
MOUSE MODEL OF PALATABLE DIET ALTERNATION  
GABRIELLE STAR SCHLAIN 
ABSTRACT 
 
Obesity and eating disorders represent a severe problem in Western societies. 
Both the increased availability of highly palatable foods and dieting are major risk factors 
contributing to the epidemic disorders of feeding. The purpose of this study was to 
characterize an animal model of maladaptive feeding induced by intermittent access to a 
palatable diet alternation in mice. In this study, mice were either continuously provided 
with standard chow food (Chow/Chow), or provided with standard chow for 2 days, with 
1 day of access to a high-sucrose, palatable food (Chow/Palatable). Following stability of 
intake within the cycling paradigm, we investigated the effects of several 
pharmacological treatments: Naltrexone, an opioid antagonist, SR141716A (rimonabant), 
a type 1 cannabinoid receptor antagonist, and BD-1063, a type 1 sigma receptor 
antagonist. Over successive cycles, Chow/Palatable mice showed an escalation of 
palatable food intake within the first-hour of renewed access to palatable diet, and 
displayed hypophagia upon its removal. Naltrexone, SR141716A, and BD-1063 reduced 
overconsumption of palatable food during this first hour. Here we provide evidence of 
strong face and convergence validities in a palatable diet alternation model in the mouse, 
confirming multiple shared underlying mechanisms of pathological eating across species, 
and thus making it a useful therapeutic development tool.   
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INTRODUCTION 
 
Obesity and Eating Disorders 
 Pathological eating is an underlying construct of some forms of obesity and 
certain eating disorders, such as binge eating disorder (BED), as well as the recently 
proposed food addiction (Dore et al., 2014). It is well known that the prevalence of 
obesity is increasing at an alarming rate (Jacobsen & Aars, 2015). Obesity is diagnosed 
when an individual exhibits a body mass index, or BMI, of 30 or above (World Health 
Organization, 2000). BMI is calculated as the body weight divided by the square of the 
height, and is expressed in kg/m2 (World Health Organization, 2000). According to the 
Center for Disease Control and Prevention (CDC), 36.5% of adults in the United States 
are obese (CDC, 2014). Obesity not only impacts quality of life, but it also increases risk 
of developing type 2 diabetes, heart disease, stroke, and many other life-threatening 
conditions (CDC, 2014).  
 BED became an official mental health diagnosis when the American Psychiatric 
Association included the disorder in the DSM-5 in 2013 (APA, 2000). Diagnostic criteria 
include: frequent and sustained episodes of binge eating, eating excessive portions of 
food when not physically hungry, eating more rapidly than normal, eating alone due to 
the embarrassment of overeating, eating to a point of discomfort, disgust, depression 
and/or guilt, a general state of distress, and absence of normal compensatory behaviors, 
such as purging (Herman et al., 2016; Pawaskar et al., 2016).  
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Highly Palatable Foods  
A factor contributing to the epidemic disorders of feeding is the increased 
availability and addictive potential of highly palatable food (food rich in sugars and/or 
fats) (Avena & Gold, 2011; Berthoud, 2012; Gearhardt et al., 2011). Highly palatable 
foods are strong positive reinforcers. A behavior is said to be positively reinforced when 
the outcome is favorable enough to increase its occurrence (Ferster, 2002). The 
reinforcing efficacy of a palatable diet is motivated by the pleasure derived from its 
consumption (Berridge, 1996). 
Elevated levels of dopamine and opioids are responsible for the positive 
reinforcing properties of a palatable diet, strengthening behaviors that are performed to 
obtain and consume palatable food (Bassareo & Di Chiara, 1999; Colantuoni et al., 2002; 
Kelley, Bakshi, Fleming, & Holahan, 2000; Rada, Avena, & Hoebel, 2005; Wang et al., 
2011). However, repeated overconsumption of palatable food may result in 
overstimulation of the reward system, whereby compensatory mechanisms drive to 
desensitize the system and thus dampen the natural reward response (Alsio et al., 2010; 
Koob, 2013; Moore, Sabino, Koob, & Cottone, 2017; Stice, Yokum, Blum, & Bohon, 
2010). In order to continue receiving even basal levels of reward, eating must entail an 
overconsumption of fat and sugar, especially after a brief period of dieting (Curtis & 
Davis, 2014; Everitt & Robbins, 2005; Kekic et al., 2014; Marco, Schroeder, & Weller, 
2012; Ng & Davis, 2013; Pelchat, Johnson, Chan, Valdez, & Ragland, 2004; Sharma, 
Fernandes, & Fulton, 2013). 
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Palatable Diet Alternation 
Another factor which is recognized as a major contributor for obesity and eating 
disorders is dieting (Dulloo & Montani, 2015; Lowe, Doshi, Katterman, & Feig, 2013). 
Dieting often refers to limiting dietary intake to low-calorie, “safe” foods, which are 
broadly less palatable than high-calorie foods, and abstaining from “forbidden” foods of 
high-calorie content and often high palatability (Hofmann, Adriaanse, Vohs, & 
Baumeister, 2014; Mela, 2001). Ultimately, those who diet, or abstain from palatable 
food, will return to foods of high palatability when diets fail (Pankevich, Teegarden, 
Hedin, Jensen, & Bale, 2010). Thus, a history of dieting is characterized by repeated, 
discrete alternations in intake of “safe” foods with highly palatable foods, rich in fat 
and/or sugar (Laessle, Tuschl, Kotthaus, & Pirke, 1989; Mela, 2001; Polivy & Herman, 
1985).  
Because the origin of pathological overeating is still largely unknown, current 
food cycling models are said to be isomorphic, in that they aim to replicate human’s 
symptoms rather than causations (Corwin & Buda-Levin, 2004). In preclinical behavioral 
laboratories, an experimental paradigm commonly used to mimic the outcomes of diet 
alternation as observed in human dieters is to provide intermittent access to highly 
palatable diets (Corwin & Buda-Levin, 2004). By temporarily restricting access to highly 
palatable diets, animals are more likely to binge eat upon their reintroduction (Corwin & 
Buda-Levin, 2004). In these models, chow and water are always presented ad libitum, 
while an additional palatable diet is supplied sporadically, in time-sensitive intermittent 
periods (Corwin, 2004; Corwin, Avena, & Boggiano, 2011; Giuliano & Cottone, 2015). 
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As such, displays of escalation in palatable food intake are considered independent from 
a state of hunger, and instead indicative of a preference for the more rewarding palatable 
diet (Cottone, Sabino, Steardo, & Zorrilla, 2008). Palatable food exposure can vary in 
length, where brief access extends a maximum of 2 hours and can therefore be regarded 
as “binge-like” eating, while extended access is continued for a minimum of 24 hours to a 
few days (Corwin et al., 2011; Corwin & Buda-Levin, 2004).  
Our lab has employed a different experimental paradigm to mimic dieting 
outcomes, a model characterized by extended, alternating access to a highly palatable diet 
in male Wistar rats (Dore et al., 2014). This model consists of a three-day procedure 
which cycles between access to two different diets, standard lab chow and a high-sucrose, 
chocolate flavored palatable diet (Dore et al., 2014). In this paradigm, palatable food 
renewal during the intermittent access phase results in excessive consumption, up to 
~7.5-fold that of control rats eating standard chow (Dore et al., 2014). This escalation of 
intake within the first hour of reintroduction mimics what is often seen in models of drug 
addiction (Ahmed & Koob, 1998). Furthermore, when palatable food is no longer 
available, but standard chow is available ad libitum, diet cycled animals will reject the 
standard chow, displaying profound hypophagia (Cottone et al., 2008; Dore et al., 2014). 
Importantly, no experimental food restriction/deprivation is used, and, therefore, the 
observed hypophagia is a spontaneous eating adaptation induced by switching from the 
high-reward food (i.e. highly palatable diet) to the low-reward food (i.e. standard chow 
diet).  
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Neurobiological Mechanisms 
There are several key brain areas involved in pathological feeding behavior, 
including the basal ganglia, the extended amygdala, and the prefrontal cortex (PFC) 
(Baik, 2013; Bassareo & Di Chiara, 1999; Oades, 1981; Stice, Figlewicz, Gosnell, 
Levine, & Pratt, 2013; Yoshida et al., 1992). These regions direct various relevant 
psychological processes, such as reward and reinforcement learning, emotional 
processing, and inhibitory control (Moore et al., 2017). The basal ganglia, consisting of 
the nucleus accumbens (NAc) and ventral tegmental area (VTA) of the midbrain, is 
responsible for the rewarding properties and reinforcing efficacy of palatable food 
consumption (Avena, Rada, & Hoebel, 2008; Koob, 2015; Volkow, Wang, & Baler, 
2011). Thus, eating highly palatable foods is initially positively reinforced through VTA 
to NAc dopaminergic signaling (Wise, 2013). However, following a history of repeated 
overconsumption, this intermittent dopamine activation is hypothesized to result in an 
eventual downregulation of the reward system, and dampening of the rewarding 
properties of palatable foods (Johnson & Kenny, 2010; Kenny, Voren, & Johnson, 2013). 
In addition, repeated cycles of overeating and withdrawal from palatable food recruits 
brain stress systems in the extended amygdala, causing an anxiety and depressive state 
when palatable food is removed (Iemolo et al., 2012; Koob, 2015). Neuroadaptations in 
the PFC, a brain region involved in inhibitory control processes (Boeka & Lokken, 2011; 
Volkow et al., 2008), can lead to dysfunction in controlling food seeking and 
consumption, even in the face of negative consequences (Oswald, Murdaugh, King, & 
Boggiano, 2011). The most promising pharmacotherapies for pathological eating would 
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exert their therapeutic effects through modulation of one of these processes (reward and 
reinforcement learning, emotional processing, and/or inhibitory control). In the 
experiments presented, we used pharmacological treatments that have shown efficacy in 
reducing palatable food intake in a rat model of palatable food alternation, and that have 
hypothesized underlying mechanisms related to pathological, compulsive eating.  
 
Opioid System 
The opioid system consists of several opioid receptor subtypes: delta, kappa, and 
mu (Bakshi & Kelley, 1993; Paterson, Robson, & Kosterlitz, 1983). Stimulation of these 
opioid receptors within the NAc by use of potent agonists found all three to increase food 
intake, yet mu-opioid receptor agonists specifically motivated consumption of highly 
palatable foods (Bakshi & Kelley, 1993; Katsuura & Taha, 2010; Kelley, Bless, & 
Swanson, 1996; Paterson et al., 1983; Zhang, Gosnell, & Kelley, 1998). Peculiarly, mu-
opioid receptor antagonists have distinctively shown to decrease palatable food intake, 
while delta-opioid receptor antagonists have shown to increase intake and kappa-opioid 
receptor antagonists have not been demonstrated to exert an effect whatsoever (Kelley et 
al., 1996). 
The opioid system is, therefore, in part responsible for the hedonic properties of 
palatable foods (Kelley et al., 2000), as well as maladaptive, or compulsive, eating 
behavior (Blasio, Steardo, Sabino, & Cottone, 2014). High levels of endogenous opioid 
peptides and their receptors are found within the limbic, forebrain, and brainstem brain 
areas (Kelley et al., 2000). Mu-opioid receptors are highly distributed within the NAc and 
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PFC; it is within the NAc that mu-opioid receptors are important for enhancing the 
“hedonic,” or pleasurable, value of food (Eikemo et al., 2016; Kelley et al., 2000; Marco 
et al., 2012; Taha et al., 2006).  
This laboratory has previously investigated the potential involvement of opioid-
driven overconsumption through the effects of Naltrexone, a mu-opioid antagonist 
(Blasio et al., 2014). Indeed, in a rat model of palatable diet alternation, systemic 
administration of Naltrexone resulted in a nonspecific reduction of eating of both 
standard food (chow) and palatable food (Blasio, Steardo, Sabino, & Cottone, 2014), 
attributable to a decline in the rewarding properties of, and motivation to consume, food 
(Blasio et al., 2014; Eikemo et al., 2016; Kelley et al., 2000). Conversely, administration 
of Naltrexone into the PFC was found to dose-dependently decrease the intake of a highly 
palatable diet, but not standard chow (Blasio, Steardo, Sabino, & Cottone, 2014) or 
compulsive eating (Cottone et al., 2012). In addition, following a schedule of limited 
access to a highly palatable diet in which modeled compulsive-like behavior, gene 
expression of the opioid peptide proopiomelanocortin (POMC) was found to be elevated, 
while gene expression of prodynorphin (PDyn) in the medial PFC was found to be 
diminished (Cottone et al., 2012). It is hypothesized that these responses are the result of 
disrupted self-control within the PFC (Mena, Sadeghian, & Baldo, 2011; Mena, Selleck, 
& Baldo, 2013; Selleck et al., 2015). Therefore, antagonizing the opioid system provides 
an opportunity to prevent overconsumption of highly palatable food. 
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Cannabinoid-1 Receptor (CB1) System 
Endocannabinoids normally function as retrograde synaptic messengers, acting 
within the brain’s hippocampus, cerebellum, limbic, and mesocortical systems (Fride, 
2002). Two major cannabinoid receptors, CB1 and CB2, are activated by cannabinoid 
binding and thereafter influence many downstream signaling transduction pathways, such 
as adenylate cyclase, mitogen-activated protein kinase, and ion channels (Ameri, 1999; 
Matsuda, Lolait, Brownstein, Young, & Bonner, 1990; McAllister & Glass, 2002). CB1 
is the most abundant cannabinoid receptor in the brain, often referred to as the “brain 
cannabinoid receptor” (Howlett, 1995), and regulates emotions, appetite, reward, and 
memory (Breivogel & Childers, 1998; Matsuda et al., 1990). Previous findings have 
shown that the endocannabinoid anandamide successfully enhanced appetite in a central 
CB1-dependent manner (Berry & Mechoulam, 2002; Williams & Kirkham, 1999). 
Endogenous ligands targeting CB1 receptors have shown to increase dopamine in the 
NAc (Solinas, Justinova, Goldberg, & Tanda, 2006), a brain area responsible for hedonic 
properties of reward (Mahler, Smith, & Berridge, 2007). By stimulating the reward 
pathway, endocannabinoids may promote food overconsumption (Kunos, Osei-Hyiaman, 
Liu, Godlewski, & Batkai, 2008). Given the role of the endocannabinoid system in the 
modulation of appetite and energy metabolism, CB1 has been regarded as a highly 
potential target for appetite suppressant pharmacotherapy. SR141716A, a CB1 receptor 
antagonist, has been extensively studied as a drug to combat obesity since its discovery, 
due to its influence on homeostatic feeding and food reward (Matias & Di Marzo, 2007). 
Indeed, SR141716A has been shown to reduce both intake of a highly palatable diet and 
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body weight in rats with a history of intermittent exposure to a palatable diet (Dore et al., 
2014). SR141716A has additionally been shown to exert longer-lasting reduction of body 
weight than its anorectic effects, suggesting a surge in energy expenditure (Colombo et 
al., 1998). Thus, the endocannabinoid system is a promising therapeutic target for obesity 
and eating disorders (D'Addario et al., 2014; Lupica & Riegel, 2005). 
However, SR141716A was taken off of the market due to side-effects, including 
depression and anxiety in some dieters (Christensen, Kristensen, Bartels, Bliddal, & 
Astrup, 2007; Hillard, Weinlander, & Stuhr, 2012). We recently hypothesized that in 
situations of pathological overeating, the endocannabinoid system is recruited to cope 
with the amygdala-driven stress of withdrawal (Hillard et al., 2012). Accordingly, an 
upregulation of CB1 receptors within the central nucleus of the amygdala have been 
found in palatable-withdrawn rats (Blasio et al., 2013). As endocannabinoids are believed 
to ease a negative affective state of withdrawal, blockade of CB1 signaling results in a 
precipitation of anxiety and depressive symptoms.  
 
Sigma-1 Receptor (Sig1R) System 
Sig1Rs have more recently been redefined as a distinct class of chaperones 
located within the endoplasmic reticulum and in high concentration within the striatum of 
the brain (Alonso et al., 2000; Hayashi & Su, 2005). Previous studies have also 
demonstrated that Sig1Rs elevate dopamine levels within the NAc shell and frontal 
cortex (Fu et al., 2010; Gronier & Debonnel, 1999; J.-J. Liu et al., 2015; Navarro et al., 
2010). 
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Sig1Rs, known to shape drug and alcohol reinforcement (Robson, Noorbakhsh, 
Seminerio, & Matsumoto, 2012; Sabino et al., 2009), also appear to influence excessive 
and compulsive-like eating in animals (Cottone et al., 2012). Previous experiments 
demonstrate that the Sig1R antagonist, BD-1063, selectively and dose-dependently 
decreased binge-like eating of palatable food (Cottone et al., 2012). Additionally, Sig1R 
antagonism fully blocked compulsive-like eating in rats with a history of intermittent 
access to palatable food (Cottone et al., 2012).  
 
Goal of Study 
 Our first aim of this study was to validate the face validity of a model of 
intermittent cycling access of palatable food in male mice (Blasio, Rice, et al., 2014; 
Cottone et al., 2008; Dore et al., 2014). Our second aim of this study was to evaluate the 
convergent validity of the diet alternation model by testing drugs which have been 
previously demonstrated to block excessive eating of highly palatable food in other diet 
alternation models. In particular, we tested Naltrexone, an opioid antagonist, SR141716A 
(rimonabant), a type 1 cannabinoid receptor antagonist, and BD-1063, a type 1 sigma 
receptor antagonist, all of which have been shown to successfully reduce excessive intake 
of palatable food in other rodents modes (Blasio, Rice, et al., 2014; Blasio, Steardo, et al., 
2014; Cottone et al., 2012; Dore et al., 2014). It was hypothesized that the results of this 
study would provide evidence for the model to hold strong face and convergent validities 
(Blasio, Rice, Sabino, & Cottone, 2014; Blasio, Steardo, et al., 2014; Cottone et al., 2012; 
Dore et al., 2014).
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METHODS 
 
Mice 
Male C57Bl/6J mice (N=73), (7 weeks old upon arrival, Jackson labs) weighing 
22-29 g, were single housed in wire-topped, plastic cages (16.76 × 27.94 × 12. 32cm3) on 
a 12-hour reverse light cycle (lights off at 10:00 a.m.), in an AAALAC-approved 
humidity- (60%) and temperate-controlled (22°C) vivarium. Mice had access to a pre-
measured amount of corn-based chow and water ad libitum at all times unless otherwise 
stated. All experimental protocols used in this study were permitted by the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and the Principles 
of Laboratory Animal Care, and were in accordance with the Boston University Medical 
Campus Institutional Animal Care and Use Committee. The experimental protocols did 
not include food or water restriction/deprivation. 
 
Food 
Corn-based chow (Teklad Global Diet 2918 (44.2% carbohydrate, 6.2% fat, 
18.6% protein, metabolizable energy 3.3 cal/g; Harlan, Indianapolis, IN) was used as the 
control diet. A highly palatable and nutritionally complete, chocolate-flavored, high-
sucrose, AIN-76A-based diet, comparable in macronutrients and energy density to the 
chow diet (Formula 5TUL: 66.7% carbohydrate, 12.7% fat, 20.6% protein, metabolizable 
energy 3.44 cal/g; TestDiet, Richmond, IN), was used as the experimental diet. 
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Palatable Diet Cycling 
An intermittent palatable diet access paradigm was used, similar to the one 
previously described in rats (Blasio, Rice, et al., 2014; Dore et al., 2014). After arrival 
and one-week acclimation period, mice were divided into two experimental diet groups 
matched for food intake, body weight and feed efficiency (calculated as body weight 
gain/kilocalories (kcals) consumed) from a 4-day baseline period. One diet group had ad 
libitum access to the chow diet (‘Chow’) (Chow/Chow) at all times, while the other diet 
group had ad libitum access to the chow diet for 2 days, followed by a single day of ad 
libitum access to the more palatable, chocolate-flavored, high-sucrose diet (‘Palatable’; 
Chow/Palatable). The Chow/Chow diet group served as a control for all comparisons and 
analysis against the experimental Chow/Palatable diet group. For concision, the first 2 
days (chow diet only) and the following 1 day (chow or palatable diet according to diet 
group) are referenced in all experiments as C and P Phases, respectively. Diets were 
never simultaneously available in any single cage. Diet switch occurred before lights 
turned off at 10:00 a.m. Food intake and body weight were measured at the onset of each 
successive phase, when the Chow/Palatable diet group would be switched from one diet 
to the other. An additional food intake measurement took place for both diet groups 1-
hour following the onset of each P Phase, to serve as an evaluation for the escalation of 
palatable diet consumption. Average food intake was determined as the kcal intake in a 
particular phase divided by how many days the phase spanned (2 for C Phase, 1 for P 
Phase). Average body weight change was computed as the difference between the body 
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weight at the end of a phase and the body weight from the beginning of that phase 
divided by the number of days included in that phase. Average and cumulative feed 
efficiencies were determined by body weight (g) gained in a given time interval (single 
phase or complete cycle) divided by the food intake (kcal) within that same time interval. 
Cumulative food intake and cumulative body weight gain were determined as the 
difference between the food consumed (kcal) or the body weight (g) achieved by the end 
of a complete cycle and that from the beginning of the study. The 5TUL Chocolate Diet 
(sugary palatable diet) was uniformly preferred compared to the Harlan 2918 chow mice 
(unpublished data). 
 
Drugs 
The opioid antagonist Naltrexone [(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-
dihydroxymorphinan-6-one hydrochloride] was solubilized right before treatment in 
isotonic filtered saline (0.9%) (Cole, Littleton, & Little, 2000) and administered 
intraperitoneally (0, 1 mg/kg, 10 mg/kg, 30 min pretreatment). Chosen doses and 
pretreatment time were based on previous literature (Escher & Mittleman, 2006; Moslehi 
et al., 2014; Stafford, Anderson, Shelton, & Brunzell, 2015). 
The CB1 receptor antagonist SR141716A [rimonabant or 5-(4-Chlorophenyl)-1-
(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide 
hydrochloride] was solubilized right before treatment in an 18:1:1 mixture of 
saline:ethanol:cremophor as formerly determined (Dore et al., 2014), and administered 
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intraperitoneally (0, 3 mg/kg, 10 mg/kg, 30 min pretreatment). Chosen doses and 
pretreatment time were based on previous literature (Dol-Gleizes et al., 2009; Duarte et 
al., 2004; Ward, Walker, & Dykstra, 2007; Wiley et al., 2005). 
The Sig1R antagonist BD-1063 × 2HBr salt (1-[2-(3,4-dichlorophenyl)ethyl]-4-
methylpiperazine dyhydrobromide]) was solubilized right before treatment in isotonic 
filtered saline (0.9%) (Kotagale, Mendhi, Aglawe, Umekar, & Taksande, 2013) and 
administered intraperitoneally (0, 10 mg/kg, 30 mg/kg, 15 min pretreatment). Chosen 
doses and pretreatment time were based on previous literature (Brammer, Gilmore, & 
Matsumoto, 2006; Y. Liu, Chen, Lerner, Brackett, & Matsumoto, 2005; Y. Liu & 
Matsumoto, 2008; Nguyen, Robson, Healy, Scandinaro, & Matsumoto, 2014). 
 
Pharmacological Treatment Effects on Excessive Eating of Palatable Food 
Naltrexone (0, 1 mg/kg, 10 mg/kg, i.p., −30 minutes), SR141716A (0, 3 mg/kg, 
10 mg/kg, i.p., −30 minutes), and BD-1063 (0, 10 mg/kg, 30 mg/kg, i.p., −15 minutes) 
were administered in a within-subject Latin square design. Following drug administration 
and a pretreatment period where food was withheld, mice were given access to a pre-
weighed amount of either chow or palatable diet. Food intake was measured again after 
1-hour. Body weights were recorded at time of drug administration and 24 hours after to 
evaluate drug effects on body weight. 
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Statistical Analyses 
Average daily food intake (kcal), average daily body weight change (g) and 
average daily feed efficiency (g/kcal) across 20 phases (10 cycles) were examined by 
means of 3-way mixed analyses of variance (ANOVAs) with Diet Group (Chow/Chow, 
or Chow/Palatable) as a between-subjects factor, and Phase (P Phase, or C Phase) and 
Cycle (1 to 10 cycles) as within-subject factors. First hour of palatable food consumption 
(escalation 1hr (kcal)), cumulative food intake (kcal), cumulative body weight change (g) 
and cumulative feed efficiency (g/kcal) were examined by means of 2-way ANOVAs 
with Diet Group as a between-subjects factor and Cycle as a within-subject factor. 
Pharmacological treatment effects on food intake (kcal) and body weight change (g) were 
analyzed with 2-way ANOVAs with Diet Group as a between-subjects factor and Dose as 
a within-subject factor. Post-hoc tests used were Newman-Keuls or Student’s t-test. 
Significance level is p<0.05 for all analyses. The software/graphic packages used were 
SigmaPlot 11.0 (Systat Software Inc., Chicago, IL) and Statistica 7.0 (Statsoft, Inc., 
Tulsa, OK). 
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RESULTS 
 
Effects of the Intermittent Access Cycling Model on Food Intake and Body Weight 
Alternating access to the high-sucrose, palatable diet led to progressive changes in 
food intake of mice in a diet-specific manner between the C Phase and P Phase [Cycle × 
Diet Phase × Diet Group: F(9,207)=10.71, p<0.001]. Excessive intake (kcal) occurred 
during the P Phase in the Chow/Palatable diet group when provided with ad libitum 
access to a palatable diet [M±SEM of P phase intake: 14.85 ±0.26 kcal vs. 11.60 ±0.32 
kcal; t(23) =-7.61, p<0.001; Chow/Palatable and Chow/Chow mice, respectively, Figure 
1A], with significantly higher food intake after only the second access to palatable food 
(p<0.001). During the C Phase, food intake was lower in Chow/Palatable mice when 
provided with ad libitum access to a chow diet [M±SEM of C phase intake: 8.27 ±0.23 
kcal vs. 11.15 ±0.28 kcal; t(23) =7.67 p<0.001; Chow/Palatable and Chow/Chow mice, 
respectively, Figure 1A], and this hypophagia was immediate, with Chow/Palatable mice 
eating significantly less after only one P Phase. However, over the course of 10 
successive cycles, Chow/Palatable mice had cumulatively eaten the same amount of food 
as Chow/Chow mice (kcal) [Diet Group: F(1,23) = 0.60, n.s.; Figure 1B], demonstrating 
that hyperphagia and hypophagia effectively canceled each other out. Similarly, while 
cumulative food intake increased across cycles [Cycle: F(9,207) =4381.72, p<0.001], this 
increase was not diet-specific [Cycle × Diet Group: F(9,207)=0.28, n.s.].  
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Mirroring food intake, daily body weight change fluctuated across 10 successive 
cycles in a phase- and diet-specific manner [Cycle × Diet Phase × Diet Group: 
F(9,207)=3.68, p<0.001; Figure 1C]. Chow/Palatable mice demonstrated greater body 
weight gain during the P Phase [M±SEM of P Phase body weight gain: 1.22±0.05 g vs. 
0.13±0.04 g; t(23) =-14.45, p<0.001; Chow/Chow and Chow/Palatable mice, 
respectively, Figure 1C], beginning after only one cycle (p<0.001). Subsequently, during 
the C Phase, Chow/Palatable mice lost body weight [M±SEM of C Phase body weight 
gain: -0.47±0.03 g vs. 0.06±0.02 g; t(23) =13.10, p<0.001; Chow/Chow and 
Chow/Palatable mice, respectively, Figure 1C]. Cumulative body weight gain (g) across 
10 cycles demonstrated differences between diet groups [Diet Group: F(1,23) =6.96, 
p<0.05; Figure 1D], across cycles [Cycle: F(9,207) =29.76, p<0.001], and an interaction 
of cycle and diet group [Cycle × Diet Group: F(9,207) =2.95, p<0.05]. Consequently, it 
may be deduced that Chow/Palatable mice fluctuated body weight as a function of the 
most recent diet in home cage (1 full cycle consists of C and then P Phase, resulting in a 
greater initial body weight gain from the first cycle in Chow/Palatable mice). Thus, body 
weight of mice increased relatively linearly with age, after the initial increase in body 
weight specific to Chow/Palatable mice during the first cycle.  
Feed efficiency (g/kcal) also fluctuated across cycles in a phase- and diet- specific 
manner [Cycle × Phase × Diet Group: F(9,207)=5.53, p<0.001; Figure 1E]. Cumulative 
feed efficiency (g/kcal) mirrored cumulative body weight change, in that this measure 
varied between diet groups [Diet Group: F(1,23)=4.32, p<0.05], across cycles [Cycle: 
F(9,207)=25.80, p<0.001] and across cycles in a diet-specific manner [Cycle × Diet 
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Group: F(9,207)=2.24, p<0.05; Figure 1F]. Therefore, this model of intermittent access to 
a palatable diet induced significant changes to food intake, body weight gain, and feed 
efficiency measures. 
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Figure 1: Effects of intermittent, extended access to a palatable diet on (A) average 
daily food intake, (B) cumulative food intake, (C) average daily body weight 
changes, (D) cumulative body weight change, (E) average daily feed efficiency, and 
(F) cumulative feed efficiency in mice (N=24). Values for C Phase represent the 
average of 2 days with access to chow diet. Data represents mean (±SEM). Symbols 
indicate significant difference between diet groups *p<0.05, **p<0.01, ***p<0.001, 
relative to Chow/Chow diet group. 
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Effects of Diet Alternation on Escalation of Palatable Food Consumption in 
Chow/Palatable Mice 
Food intake during the first hour of renewed access escalated over 10 successive 
cycles in Chow/Palatable mice [Cycle × Diet Group: F(9,207)=7.59, p<0.001; Figure 2], 
whereby during the first introduction of the palatable diet Chow/Palatable mice 
consumed more food than Chow/Chow mice in the first hour of access [t(23)=-2.54, 
p<0.05]. Overall, Chow/Palatable mice ate significantly more food (kcal) compared to 
control Chow/Chow mice during the first hour of the P Phase [Diet Group: 
F(1,23)=98.82, p<0.001; Figure 2].   
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Figure 2: Effects of intermittent, extended access to a palatable diet on food intake 
during the first hour of P Phase (when Chow/Palatable mice have access to the 
palatable diet and Chow/Chow mice have access to the standard diet). Data 
represent mean (±SEM). Symbols indicate significant difference between diet 
groups *p<0.05, ***p<0.001. 
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Effects of Naltrexone on Food Intake and Body Weight Gain  
Pretreatment with Naltrexone (1 mg/kg and 10 mg/kg, i.p., −30 minutes) 
significantly and dose-dependently reduced palatable food intake of Chow/Palatable 
mice within the first hour [Dose × Diet Group: F(2,44) =10.98, p<0.001; Figure 3A].  
The Chow/Palatable mice consumed more food under vehicle conditions than the 
Chow/Chow diet group at all doses (0, 1, 10 mg/kg), consistent with baseline conditions. 
Naltrexone did not affect chow intake of Chow/Chow mice.  
Naltrexone did not affect body weight gain, measured 24 hours after treatment 
[Dose: F(2,44) =n.s.; Dose × Diet Group: F(2,44) =n.s.; Figure 3B], though 
Chow/Palatable mice had greater body weight gain during the P Phase, as expected [Diet 
Group: F(1,22) =206.23, p<0.001]. Naltrexone therefore specifically decreased palatable 
food consumption in Chow/Palatable mice, without affecting body weight gain. 
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Figure 3: Effects of pretreatment (-30 min) with opioid antagonist Naltrexone (0, 1 
mg/kg, 10 mg/kg, i.p.) on 1-hour food intake and body weight change of Chow/Chow 
and Chow/Palatable mice (n=24), respectively. Naltrexone was administered at the 
beginning of P Phase. Data represent mean (±SEM). Symbols indicate significant 
difference from vehicle-treated mice ***p<0.001 or from the 1 mg/kg Naltrexone-
treated mice of the same diet group ##p<0.01.  
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Effects of SR141716A on Food Intake and Body Weight Gain 
Pretreatment with SR141716A (3 mg/kg and 10 mg/kg, i.p., −30 minutes) 
significantly reduced palatable food intake of Chow/Palatable mice within the first hour 
[Diet Group × Dose: F(2,44) =11.66, p<0.001; Figure 4A].  Furthermore, 
Chow/Palatable mice treated with the 3 mg/kg and 10 mg/kg dose consumed an equal 
amount of food as Chow/Chow mice under vehicle conditions, indicating a complete 
blockade of excessive eating. SR141716A did not affect chow intake of Chow/Chow 
mice. The Chow/Palatable mice consumed more food under vehicle conditions than the 
Chow/Chow diet group at all doses (0, 3, 10 mg/kg), consistent with baseline conditions. 
Expectedly, SR141716A dose-dependently decreased body weight gain [Dose: 
F(2,44) =102.85, p<0.001; Figure 4B] similarly in both diet groups [Dose × Diet Group: 
F(2,44) =2.46, n.s.].  
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Figure 4: Effects of pretreatment (-30 min) with type-1 cannabinoid (CB1) receptor 
antagonist SR141716 (0, 3 mg/kg, 10 mg/kg, i.p.) on 1-hour food intake and body 
weight change of Chow/Chow and Chow/Palatable mice (n=24), respectively. 
SR141716 was administered at the beginning of P Phase. Data represent mean 
(±SEM). Symbols indicate significant difference from vehicle-treated mice *p<0.05, 
***p<0.001 or from the 3 mg/kg SR141716A-treated mice of the same diet group 
###p<0.001. 
  
 
	 26	
Effects of BD-1063 on Food Intake and Body Weight Gain 
 Pretreatment with BD-1063 (30 mg/kg, i.p., −15 minutes) significantly reduced 
palatable food intake of Chow/Palatable mice during the first hour of access [Dose × Diet 
Group: F(2,44) =18.41, p<0.001; Figure 5A]. BD-1063 did not affect chow intake of 
Chow/Chow mice. The Chow/Palatable mice consumed more food under vehicle 
conditions than the Chow/Chow diet group at all doses (0, 10, 30 mg/kg), consistent with 
baseline conditions. 
BD-1063 did not exhibit any effects on body weight gain [Dose: F(2,44) =0.48, 
n.s.; Figure 5B], though body weight change remained different between the groups, as 
expected [Diet: F(1,22) =168.18, p<0.001]. Furthermore, there were no differential 
effects of BD-1063 on body weight gain as a function of dose [Dose × Diet Group: 
F(2,44) =0.22, n.s.].  
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Figure 5: Effects of pretreatment (-15 min) with sigma-1 receptor (Sig1R) 
antagonist BD-1063 (0, 10 mg/kg, 30 mg/kg, i.p.) on 1-hour food intake and body 
weight change of Chow/Chow and Chow/Palatable mice (n=24), respectively. BD-
1063was administered at the beginning of P Phase. Data represent mean (±SEM). 
Symbols indicate significant difference from vehicle-treated mice ***p<0.001 or 
from 10 mg/kg BD-1063 treated mice ###p<0.001.   
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DISCUSSION 
 
 This study was designed to validate both the face and the convergent validities of 
a model of intermittent access to a palatable diet in the mouse. 
Our results show that, similar to what has been observed in an analogous model of 
palatable diet alternation in rats, mice show adaptations in feeding behavior characterized 
by overconsumption of the highly palatable diet and hypophagia of the less preferred 
standard chow diet. Interestingly, despite the ample oscillating nature of feeding 
behavior, palatable diet cycling mice did not eat differently than controls during the ten 
weeks of observation. 
Feeding adaptations across phases were accompanied by similar oscillating 
patterns in body weight change and feed efficiency. Notably, during the initial weeks of 
diet cycling, cumulative body weight and feed efficiency of Chow/Palatable mice were 
significantly higher than Chow/Chow controls. However, these differences slowly 
decreased over time, so that starting from week 7 and week 4 the two experimental 
groups did not differ in cumulative body weight and feed efficiency, respectively. 
While the results shown here using the present mouse model of diet alternation 
well replicates previous observations in rat models, it is also important to underline some 
important differences between the two species. Indeed, while we have repeatedly 
observed that local alterations in food intake, body weight, and feed efficiency in the rat 
developed slowly and progressively across weeks of diet alternation (Blasio, Rice, et al., 
2014; Dore et al., 2014), here we observed that local adaptations in food intake, body 
weight, and feed efficiency in the mouse were robust since the first switch in diets (either 
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chow to palatable or palatable to chow), and were not different across weeks of cycling. 
These results suggest that the behavioral outcomes in response to changes in food 
palatability develop more vigorously and more quickly in mice than in rats.  
We observed that within the first hour of renewed access to palatable food, 
Chow/Palatable mice exhibited excessive (>3 times greater) eating behavior compared to 
chow. Excessive intake of palatable diet during the first hour of renewed access to 
palatable food escalated slowly across cycles, similar to what has been observed in rats 
(Blasio, Rice, et al., 2014; Dore et al., 2014). Escalation of food consumption has been 
frequently interpreted as a hallmark of the addictive properties of highly palatable food 
(Blasio, Rice, et al., 2014; Cottone et al., 2012; Dore et al., 2014), given the similarity to 
what is observed in animal models of drug addiction (Ahmed & Koob, 1998; Greenwell, 
Walker, Cottone, Zorrilla, & Koob, 2009; Lopez & Becker, 2014). 
Furthermore, we wanted to validate the convergent validity of the present mouse 
model of palatable diet alternation by testing the effects of drugs which have been 
demonstrated to be effective in reducing excessive food intake in other validated models 
of palatable diet alternation (Blasio, Rice, et al., 2014; Blasio, Steardo, et al., 2014; 
Cottone et al., 2012; Dore et al., 2014). For this purpose, we administered Naltrexone, an 
opioid antagonist, SR141716A, a CB1 receptor antagonist, and BD-1063, a Sig1R 
antagonist, before renewing access to the highly palatable diet. 
We observed that pretreatment with Naltrexone dose-dependently reduced 
palatable food intake of Chow/Palatable mice. The effects of Naltrexone were selective 
for palatable diet cycled mice, as drug administration did not affect food intake of 
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controls. Naltrexone treatment did not alter body weight change in either diet cycled mice 
or controls. Our results were consistent with previous observations, which show that 
pretreatment with Naltrexone dose-dependently reduced binge eating in male rats (Blasio, 
Steardo, et al., 2014; Eikemo et al., 2016; Kelley et al., 2000). Additionally, Naltrexone 
lowered the motivation for obtaining food, as measured by a progressive-ratio schedule 
of reinforcement in an operant conditioning model (Blasio, Steardo, et al., 2014; Eikemo 
et al., 2016; Kelley et al., 2000). While our experiments did not clarify which brain area 
is responsible for the observed effects following Naltrexone administration, previously 
published papers help us speculate that cortico-limbic areas may be involved. Indeed, 
when Naltrexone was microinfused either into the medial PFC or the NAc, the drug was 
able to reduce excessive intake of palatable food in a rodent model of binge eating, 
induced by limiting access of highly palatable food to 1-hour each day (Blasio, Steardo, 
et al., 2014). Notably, in this study, Naltrexone selectively reduced palatable diet intake 
only when microinfused into the PFC, while when microinfused into the NAc it affected 
both the standard chow and palatable diets (Blasio, Steardo, et al., 2014). 
 Pretreatment with SR141716A dose-dependently blocked excessive eating of 
palatable food by mice in the Chow/Palatable diet group. The intake of Chow/Palatable 
mice after pretreatment with SR141716A (3 and 10 mg/kg) was no different than that of 
the Chow/Chow mice under vehicle conditions. Drug administration tended to reduce 
control intake in the Chow/Chow group, but this reduction did not reach statistical 
significance. Consistent with an effect of SR141716A on energy expenditure (Herling, 
Kilp, Elvert, Haschke, & Kramer, 2008), drug treatment was accompanied by a reduction 
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in body weight change in both Chow/Chow and Chow/Palatable mice. Our results 
confirm previous observations in rats, in which SR141716A pretreatment more potently 
reduced 1-hour food intake of Chow/Palatable animals, as well as induced a greater body 
weight loss in Chow/Palatable animals compared to Chow/Chow animals (Dore et al., 
2014). However, it is interesting to note that palatable food consumption of female rats 
treated with SR141716A was not significantly affected (Blasio, Rice, et al., 2014), 
suggesting a potential sex-dependent selectivity in drug effects. 
Pretreatment with the Sig1R antagonist BD-1063 effectively reduced excessive 
eating at the highest dose tested. The effect of drug treatment was selective for 
Chow/Palatable mice. BD-1063 administration did not alter body weight of either diet 
cycled or control mice. Our results are in agreement with the previous observation that 
pretreatment with BD-1063 induced a selective, dose-dependent reduction of palatable 
food consumption in bingeing rats (Cottone et al., 2012). In the same study, the protein 
expression of the Sig1R protein was found to be increased in the anterior cingulate cortex 
of bingeing rats as compared to control subjects, suggesting that this area may be 
responsible for the observed pharmacological effects (Cottone et al., 2012). 
In summary, our experiments provide evidence for a novel model of palatable diet 
alternation in mice which presents strong face and convergent validity. Through repeated, 
intermittent access to a highly palatable diet, mice developed a cycling pattern of food 
intake, body weight, and feed efficiency, similar to what has been observed in rats. In 
addition, also similar to what has been observed in rats, cycled mice dramatically 
escalated intake upon renewed access to the highly palatable diet. We then further 
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validated the therapeutic potential in the application of Naltrexone, SR141716A, and BD-
1063 to effectively reduce escalated highly palatable intake. 
Finally, both the increasing availability of highly palatable foods and dieting in 
Western society pose serious risks to our health (Pinel, Assanand, & Lehman, 2000). 
These factors are indeed contributions to maladaptive forms of eating behavior in certain 
forms of eating disorders and obesity. Refinement of our preclinical animal model 
repertoire represents a critical aspect in mimicking the complexity of disordered eating, 
as well as providing effective tools for screening novel pharmacological targets.  
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